DewDiligence Wednesday, 10/28/20 11:14:47 AM Re: None Post # of 620 ABBV phase-3 trials in presbyopia hit primary endpoint: https://finance.yahoo.com/news/allergan-abbvie-company-announces-positive-120000680.html Detailed data to be presented at an unspecified medical conference. AGN-190584, a once-daily eye drop, was inherited from Allergan. “The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”